An open‐label study of rabeprazole in patients with Zollinger–Ellison syndrome or idiopathic gastric acid hypersecretion

Abstract

Rabeprazole was an effective and well-tolerated treatment for Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion, which reliably reduced gastric acid output to safe levels. Although a dose of 60 mg once daily was appropriate for most patients in this study, doses may need adjustment according to individual response.